Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1990 1
1995 2
1996 1
2001 4
2002 1
2004 1
2005 1
2006 1
2008 1
2010 3
2011 5
2012 5
2013 5
2014 9
2015 9
2016 9
2017 8
2018 11
2019 12
2020 22
2021 16
2022 9
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Verstovsek S, et al. Among authors: hus m. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. Blood Adv. 2023. PMID: 37042865 Free PMC article.
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S. Mesa R, et al. Among authors: hus m. Leukemia. 2022 Sep;36(9):2261-2268. doi: 10.1038/s41375-022-01637-7. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869266 Free PMC article. Clinical Trial.
New prognostic biomarkers in multiple myeloma.
Szudy-Szczyrek A, Szczyrek M, Soroka-Wojtaszko M, Hus M. Szudy-Szczyrek A, et al. Among authors: hus m. Postepy Hig Med Dosw (Online). 2016 Jan 4;70(0):811-9. doi: 10.5604/17322693.1211183. Postepy Hig Med Dosw (Online). 2016. PMID: 27463592 Review.
The role of immune checkpoint inhibitors in prostate cancer.
Surdacki G, Szudy-Szczyrek A, Gorący A, Chyl-Surdacka K, Hus M. Surdacki G, et al. Among authors: hus m. Ann Agric Environ Med. 2019 Mar 22;26(1):120-124. doi: 10.26444/aaem/96331. Epub 2018 Nov 21. Ann Agric Environ Med. 2019. PMID: 30922041 Free article. Review.
Momelotinib reduces transfusion requirements in patients with myelofibrosis.
Mesa R, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Palmer J, Platzbecker U, Treliński J, Shimoda K, Donahue R, D'Hollander K, Kowalski M, Verstovsek S. Mesa R, et al. Among authors: hus m. Leuk Lymphoma. 2022 Jul;63(7):1718-1722. doi: 10.1080/10428194.2022.2043304. Epub 2022 Mar 7. Leuk Lymphoma. 2022. PMID: 35255234 No abstract available.
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Szudy-Szczyrek A, Chocholska S, Bachanek-Mitura O, Czabak O, Mlak R, Szczyrek M, Muzyka-Kasietczuk J, Hus M. Szudy-Szczyrek A, et al. Among authors: hus m. Ann Agric Environ Med. 2022 Mar 21;29(1):103-109. doi: 10.26444/aaem/137788. Epub 2021 Jun 15. Ann Agric Environ Med. 2022. PMID: 35352912 Free article. Review.
130 results